---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-020447"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:17:06.043534+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ADC Therapeutics Q1 net loss narrows to $46.6M; ZYNLONTA sales $17.8M; initial MZL data shows 13/15 CR

## Summary
- ZYNLONTA net sales $17.8M in Q1 2024, up 7% QoQ, down 6% YoY; total operating expenses down 25%.
- Net loss $46.6M ($0.56/share) vs $59.4M ($0.73) in Q1 2023; adjusted net loss $31.1M.
- Cash $234.3M as of Mar 31, 2024; cash runway expected into Q4 2025.
- LOTIS-5 enrollment on track to complete in 2024; LOTIS-7 dose escalation complete, expansion initiated.
- Initial Phase 2 IIT data in r/r MZL: 15 evaluable patients, 13 complete responses (CR) and 1 PR.

## SEC filing metadata
- accession: 0001628280-24-020447
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000162828024020447/0001628280-24-020447-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000162828024020447/adc-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-020447
- JSON: https://secwatch.observer/filing/0001628280-24-020447.json
- Plain text: https://secwatch.observer/filing/0001628280-24-020447.txt

## Key facts
- Earnings Releases
  ADC Therapeutics SA reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 6, 2024, ADC Therapeutics SA (the “Company”) issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1771910/000162828024020447/0001628280-24-020447-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.